



ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference

September 14, 2022

SAN CLEMENTE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- [ReShape Lifesciences](#)™ (Nasdaq: RSL5) the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer and Tom Stankovich, Chief Financial Officer, will be participating in one-on-one meetings with institutional investors during the A.G.P. Virtual MedTech Conference, taking place Thursday, September 21, 2022.

Investors participating in the virtual conference who are interested in meeting with ReShape's management team should contact their A.G.P. representative.

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. Reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. For more information, please visit www.reshapelifesciences.com,

CONTACTS

ReShape Lifesciences Investor Contact:

Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapelifesci.com

Investor Relations Contact:

Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com



Source: ReShape Lifesciences Inc